Relative Mr determination and relative ion abundance ratio of MIP-1α isoform mass spectra obtained by MALDI-TOF and LC-ESI-MS analyses
| . | LC-ESI-MS* . | MALDI-TOF-MS† . | ||
|---|---|---|---|---|
| tMIP-1α . | iCCL3L1 . | tMIP-1α . | iCCL3L1 . | |
| rCCL3/rCCL3L1 | 7442 ± 7 | 7796 ± 6 | ND | ND |
| HTLV-2/HIV-1MEU | 7444 ± 6 | 7794 ± 6 | 7456 ± 7 | 7808 ± 8 |
| . | LC-ESI-MS* . | MALDI-TOF-MS† . | ||
|---|---|---|---|---|
| tMIP-1α . | iCCL3L1 . | tMIP-1α . | iCCL3L1 . | |
| rCCL3/rCCL3L1 | 7442 ± 7 | 7796 ± 6 | ND | ND |
| HTLV-2/HIV-1MEU | 7444 ± 6 | 7794 ± 6 | 7456 ± 7 | 7808 ± 8 |
The results shown are the average relative Mr (n = 6) expressed in Da together with their standard deviation. These data derived from 5 independent experiments performed on recombinant isoforms and on purified MIP-1α immunoreactive fractions from HTLV-2/HIV-1MEU subjects.
tMIP-1α indicates truncated CCL3 or CCL3L1 isoform, 66 residues; iCCL3L1, natural, intact CCL3L1 isoform, 70 residues; ND, not determined.
iCCL3L1 on tMIP-1α = 0.55 ± 0.03, determined with the following formula: [IiCCL3L1/(IiCCL3L1 + ItMIP-1α)] where I is intensity of the [M]+3 signal.
iCCL3L1 on tMIP-1α = 0.62 ± 0.01, determined with the following formula: [IiCCL3L1/(IiCCL3L1 + IrMIP-1α)].